1. Aprea secures $3.1 million from new and existing investors. 2. Funding extends cash runway into Q1 2027, supporting clinical development. 3. The offering price is set at $1.165 per share, with warrants included. 4. Proceeds will be used for general corporate and R&D expenses. 5. Aprea focuses on cancer treatments targeting specific cell vulnerabilities.
FAQ
Why Bullish?
The financing indicates investor confidence, potentially raising stock demand and price. Similar funding events have historically led to stock price increases for biopharmaceutical firms.
How important is it?
The article discusses significant financing that impacts Aprea's operational capabilities, suggesting a strategic position to develop its cancer therapies.
Why Long Term?
The cash runway supports long-term research initiatives, potentially leading to marketable products. Successful clinical trials in the future could significantly enhance valuation.
Aprea Therapeutics Secures $3.1 Million in Private Placement
DOYLESTOWN, Pa., December 09, 2025 – Aprea Therapeutics, Inc. (Nasdaq: APRE), a pioneering biopharmaceutical company focused on cancer treatments, has announced a significant private placement aimed at extending its financial runway into 2027.
Details of the Private Placement
Aprea Therapeutics has entered into a securities purchase agreement with both new and existing healthcare investors, involving the sale of 2,623,023 shares of common stock or equivalent pre-funded warrants. Each share comes with a warrant to purchase an additional share, all priced at an effective rate of $1.165.
The accompanying warrants will have an exercise price of $1.04 per share. They can be exercised immediately upon issuance and will remain valid until the five-year anniversary of the issuing registration statement.
Financial Implications and Use of Proceeds
The estimated gross proceeds from this offering amount to approximately $3.1 million, which will be utilized for various corporate objectives, including ongoing research and development initiatives. Aprea is optimistic that these funds will support its operational activities through Q1 2027.
The closing of the offering is projected to occur on or around December 10, 2025, pending the customary closing conditions.
Placement Agent and Regulatory Information
Maxim Group LLC has been appointed as the sole placement agent for this offering. The securities involved in this private placement are not registered under the Securities Act of 1933 and may not be offered or sold in the U.S. unless authorized by an effective registration statement or under applicable state securities laws.
Aprea Therapeutics will file a registration statement with the Securities and Exchange Commission to register the resale of these securities, ensuring compliance with necessary regulations.
About Aprea Therapeutics
Aprea Therapeutics is at the forefront of developing innovative cancer treatments that target specific vulnerabilities in cancer cells while preserving healthy cells. Its lead clinical programs include APR-1051, an oral inhibitor of WEE1 kinase, and ATRN-119, an ATR inhibitor, both aimed at treating various solid tumors.
The company’s technology offers potential benefits across numerous cancer types, including ovarian, endometrial, colorectal, prostate, and breast cancers.
Forward-Looking Statements
This announcement contains forward-looking statements regarding Aprea Therapeutics’ financial position, clinical development plans, and cash runway. These statements are based on current expectations and assumptions from the company’s management and involve various risks that could lead to different outcomes.